Skip to main content

Table 1 Indications Included in Identified Studies by Intervention

From: Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment

DrugIndication(s)
CTLA-4 inhibitors
 IpilimumabMelanoma (n = 25), NSCLC (n = 3), mCRC (n = 1), SCLC (n = 1), RCC (n = 1), pancreatic (n = 1)
 TremelimumabMelanoma (n = 3)
PD-1 inhibitors
 NivolumabNSCLC (n = 14), melanoma (n = 14), RCC (n = 3), urothelial (n = 2), SCCHN (n = 1), GC (n = 1), mCRC (n = 1), Hodgkin’s disease (n = 1), SCLC (n = 1)
 PembrolizumabMelanoma (n = 9), NSCLC (n = 6), urothelial (n = 2), mCRC (n = 2), GC (n = 1), breast cancer (n = 1), SCCHN (n = 1)
PD-L1 inhibitors
 AtezolizumabNSCLC (n = 6), melanoma (n = 2), urothelial (n = 3), RCC (n = 2)
 AvelumabNSCLC (n = 1), Merkel cell cancer (n = 1), urothelial (n = 1)
 DurvalumabNSCLC (n = 2), urothelial (n = 1)
  1. CTLA-4 cytotoxic T-lymphocyte-associated protein 4; GC gastric cancer; mCRC metastatic colorectal cancer; NSCLC non-small cell lung cancer; PD-1 programmed cell death protein 1; PD-L1 programmed death ligand 1; RCC renal cell cancer; SCCHN squamous-cell carcinoma of the head and neck; SCLC small cell lung cancer